Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CORVax12
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : OncoSec Immunotherapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company's DNA-encodable vaccine candidate for COVID-19.
Product Name : CORVax12
Product Type : Vaccine
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : CORVax12
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : OncoSec Immunotherapies
Deal Size : Undisclosed
Deal Type : Licensing Agreement